57999-46-9

Basic information

• Product Name: 2-(2'-BROMOPHENOXY)TETRAHYDRO-2H-PYRAN
• Synonyms: 2-(2'-BROMOPHENOXY)TETRAHYDRO-2H-PYRAN
• CAS NO: 57999-46-9
• Molecular Formula: C₁₁H₁₃BrO₂
• Molecular Weight: 257.12
• Product Categories: Bromine Compounds;Miscellaneous Compounds
• Mol File: 57999-46-9.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(2'-BROMOPHENOXY)TETRAHYDRO-2H-PYRAN(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2'-BROMOPHENOXY)TETRAHYDRO-2H-PYRAN(57999-46-9)
• EPA Substance Registry System: 2-(2'-BROMOPHENOXY)TETRAHYDRO-2H-PYRAN(57999-46-9)

Safety Data

• Hazardous Substances Data: 57999-46-9(Hazardous Substances Data)

Usage

Structure

Tetrahydropyran derivative with a bromophenoxy group

Potential uses

Building block in organic synthesis, precursor in pharmaceutical and agrochemical industries, materials science, and other industrial applications

Versatility

Can be utilized in various fields of research and industry

Upstream product

• 110-87-2 3,4-dihydro-2H-pyran 
• 95-56-7 2-hydroxybromobenzene 

Downstream Products

• 86259-60-1 2,5-Dimethyl-2-(2-hydroxyphenyl)-3,4-dihydro-2H-pyrrole 1-Oxide 
• 97150-94-2 1-[4-(2-Dimethylamino-ethoxy)-phenyl]-2-phenyl-1-[2-(tetrahydro-pyran-2-yloxy)-phenyl]-butan-1-ol 
• 97135-10-9 1-(4-methoxyphenyl)-1-<2-(tetrahydropyran-2-yloxy)phenyl>-2-phenyl-1-butanol 
• 620987-99-7 C₁₇H₂₇BO₄ 
• 1193444-27-7 C₁₇H₂₂O₅ 

Relevant articles and documents

Design, synthesis and biological evaluation of 2-substituted-6-[(4-substituted-1-piperidyl)methyl]-1H-benzimidazoles as inhibitors of ebola virus infection

Novel 2-substituted-6-[(4-substituted-1-piperidyl)methyl]-1H-benzimidazoles were designed and synthesized as Ebola virus inhibitors. The proposed structures of the new prepared benzimidazole-piperidine hybrids were confirmed based on their spectral data and CHN analyses. The target compounds were screened in vitro for their anti-Ebola activity. Among tested molecules, compounds 26a (EC50=0.93 μM, SI = 10) and 25a (EC50=0.64 μM, SI = 20) were as potent as and more selective than Toremifene reference drug (EC50 = 0.38 μM, SI = 7) against cell line. Data suggests that the mechanism by which 25a and 26a block EBOV infection is through the inhibition of viral entry at the level of NPC1. Furthermore, a docking study revealed that several of the NPC1 amino acids that participate in binding to GP are involved in the binding of the most active compounds 25a and 26a. Finally, in silico ADME prediction indicates that 26a is an idealy drug-like candidate. Our results could enable the development of small molecule drug capable of inhibiting Ebola virus, especially at the viral entry step.

IVB group-containing bimetallic complex catalyst as well as preparation method and application thereof

The invention provides an IVB group-containing bimetallic complex catalyst as well as a preparation method and application of the catalyst. The IVB group-containing bimetallic complex has a structuralexpression shown in the specification. The IVB group-co

Metal complex, preparation method and application thereof

The invention provides a metal complex, a preparation method and application thereof. The metal complex has the following structural expression shown as the specification. The invention has the technical advantages that: the invention puts forward the O,